
SOCRUS BIO SCIENCES LIMITED
(Formerly known as TANU HEALTH CARE LTD.)

23rd ANNUAL REPORT
2012-2013

REGD. OFF: 30, 16-A, PMGP COLONY
MAHAKALI CAVE ROAD, ANDHERI(E), MUMBAI-400093

SOCRUS BIO SCIENCES LIMITED

BOARD OF DIRECTORS

1. MR. RAJEEV AGNIHOTRI : MANAGING DIRECTOR
2. MRS. MADHVI AGNIHOTRI : WHOLE TIME DIRECTOR
3. MR. SANJAY KUMAR UPADHYAY : DIRECTOR
4. MR. SUNIL KUMAR JAIN : DIRECTOR
5. MR. MANISH JAIN : DIRECTOR

AUDITORS

M/S. SHYAM NAGORI & CO.
CHARTERED ACCOUNTANT
109, KAILASH PARK COLONY
GEETA BHAWAN
INDORE (M.P.) -452 001

REGISTERED OFFICE

REGD. OFF: 30, 16-A, PMGP COLONY
MAHAKALI CAVE ROAD, ANDHERI (E),
MUMBAI (MH)- 4000 093

REGISTER & TRANSFER AGENT

M/S. BIGSHARE SERVICE PVT. LTD.
E/2, ANSA INDUSTRIAL ESTATE,
SAKI VIHAR ROAD, SAKI NAKA,
ANDHERI(E), MUMBAI-72
TEL NO.: 2852 3474 / 2856 0652

BANKERS

UNION BANK OF INDIA.

CONTENTS

Particulars	No.
Notice.....	3 to 4
Directors' Report.....	5 to 7
Corporate Governance.....	8 to 16
Auditors' Report.....	17 to 21
Balance Sheet.....	22
Statement of Profit & Loss	23
Notes Forming Part of the Balance Sheet.....	24 to 28
Notes Forming Part of Statement of Profit & Loss	29 to 31
Notes on Accounts.....	33 to 38
Cash Flow Statement.....	32
Certificate from Auditor's regarding Clause	49..39
Attendance Slip.....	40
Form of Proxy.....	40

SOCRUS BIO SCIENCES LIMITED

**REGD OFFICE: 30, 16-A PMGP COLONY,
MAHAKALI CAVE ROAD, ANDHERI (E),
MUMBAI (M.H.)**

Notice to the Shareholders

Notice is hereby given that the 23rd Annual General Meeting of the Shareholders of Socrus Bio Sciences Limited will be held on Monday 30th day of September, 2013 at 11.00 a.m. at Hotel Solitaire, Near International Airport, Opp. APT Colony, New Sanjay Nagar, Sahar Road, Chakala, Andheri (E), Mumbai-99 (MH.) to transact the following business.

ORDINARY BUSINESS

1. To receive, consider and adopt the Audited Accounts for the year ended on 31st March, 2013 and reports of Directors and Auditors thereon.
2. To appoint a director in place of Mr. Manish Kumar Jain, who retires by rotation and being eligible offers herself for re-appointment.
3. To appoint a director in place of Mr. Sunil Kumar Jain who retires by rotation and being eligible offers himself for re-appointment.
4. To appoint Auditors to hold office from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting of the company and to fix their remuneration.

BY ORDER OF THE BOARD



**Rajeev Agnihotri
Managing Director**

05th September, 2013

NOTES:

- 1) A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF AND A PROXY NEED NOT BE A MEMBER OF THE COMPANY.
- 2) Members are requested to notify immediately of any change in their address details to the Company's Registrar and share transfer agents for shares held in demat / physical form at : BIGSHARE SERVICES PRIVATE LIMITED, E/2 ANSA INDUSTRIAL ESTATE, SAKI VIHAR ROAD, SAKI NAKA, ANDHERI (EAST), MUMBAI 400 072
- 3) Proxies in order to be effective must be deposited duly stamped and signed at the Registered Office of the Company not less than 48 hours before the meeting.

4) Explanatory Statement pursuant to Section 173(2) of the Companies Act, 1956 relating to the Special Business to be transacted at the meeting is attached hereto.

5) Members are requested to :

- Contact for any query related to shares, dividend and other inquiry at the following address.

•
Bigshare Services Pvt. Ltd.
E-2, Ansa Industrial Estate,
Saki- Vihar Road, Sakinaka
Mumbai- 400 072

Contact Person : Mr. Mohan
Phone no. 022- 28470652

Quote Folio No. for any communication for their Shareholding

6). The copies of relevant documents can be inspected at the Registered Office of the Company on any working day between 11.00 a.m and 1.00 p.m up to the date of A.G.M. (i.e, upto September 30, 2013).

7). The Company's shares are presently listed at Bombay Stock Exchange Ltd.

BY ORDER OF THE BOARD



Rajeev Agnihotri
Managing Director

05th September, 2013
Mumbai

SOCRUS BIO SCIENCES LIMITED

REGD OFFICE: 30, 16-A PMGP COLONY,
MAHAKALI CAVE ROAD, ANDHERI (E),
MUMBAI (M.H.)

DIRECTORS REPORT

To,
The Members,

Your directors present herewith their 23rd Annual Report and Audited Accounts for the year ended March 31, 2013.

FINANCIAL RESULTS & PERFORMANCE

Particulars	Figures as at the end of current reporting period (In Rupees)	Figures as at the end of previous reporting period (In Rupees)
Revenue from operations and other income	198875600	301998350.00
Expenses (including material purchases and depreciation)	592497776	237447980.00
Profit before exceptional and extraordinary items and tax	(393622176)	64550370.00
Less: Profit From Biotechnology	(87844350)	65152370.00
Profit/(loss) Before Tax	(305777826)	(602000.00)
Tax Expense: Provision for Taxation	0	0.00
Add: Profit From Biotechnology	(87844350)	65152370.00
Profit/(Loss) After Tax	(-393622176)	64550370.00
Deferred Tax Assets/(Liabilities)	0	(13336821.00)
Profit/(Loss) for the period	(-393622176)	51213549.00

DIVIDEND AND BUSINESS OVERVIEW

Due to adequate investment opportunities available within the company itself your directors decided not to recommend any dividend for the year.

DIRECTORS

In accordance with the provision of Companies Act 1956 and the provision contained in the Article of association of Company Mr. **Manish Kumar Jain** and Mr. Sunil Kumar Jain being the director liable for retirement by rotation and eligible to offer for re-appointment.

Mr. Ashwin Kumar Trivedi, Director of the Company has been resigned w.e.f. 25th April 2013

Except above, there was no change in the directorship of the company during the financial year.

AUDITORS

M/S Shyam Nagori & Co., Chartered Accountants, Indore retires from the office of the Auditors and being eligible for re-appointment. The Company has received a certificate from them to the effect that the re-appointment if made will be within the limits prescribed under Section 224 (1B) of the Companies Act, 1956.

AUDITORS REPORT

The Report of Auditors of the company for the year under reference is self explanatory and do not call for any comments from the directors.

COMPLIANCE OF ACCOUNTING STANDARD

As per Clarification given in Para 4 of Auditor Report, Company has complied with all applicable Accounting Standards as per provision of section 211 (3C) of the Companies Act 1956 in its Balance Sheet and Profit & Loss Accounts.

CORPORATE GOVERNANCE

The report of the directors on Corporate Governance is given and attached herewith forming part of the directors report.

LISTING OF EQUITY SHARES

Equity shares of your company are listed on Mumbai Stock Exchange only.

DEPOSITS

The Company has not accepted deposit from public, attracting provisions of section 58A of the Companies Act, 1956 and rules made there under.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNING AND OUTGO

In terms of section 217 (1) (e) of Companies Act, 1956 and the Companies (Disclosure of particulars in the Report of Board of Directors) Rules 1988, the information under this head is given and attached herewith forming part of this report.

PARTICULARS OF EMPLOYEES

The company did not have any employee during the year drawing remuneration attracting the provisions of Section 217(2A) of the Companies Act, 1956, as amended up to date.

DIRECTOR'S RESPONSIBILITY STATEMENT

Pursuant to the requirement under Section 217 (2AA) of the Companies Act, 1956, it is hereby confirmed:

a) that in the preparation of the annual accounts for the financial year ended 31st March, 2013; the applicable accounting standards had been followed along with proper explanation relating to material departures;

b) that the directors had selected such accounting policies and applied them consistently and made judgments and estimates that were reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for the year under review;

c) that the director had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the companies Act, 1956, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d) that the directors had prepared the accounts for the financial year ended 31st March, 2013, on a "Going Concern" basis.

APPRECIATION

Your Directors also acknowledge with gratitude the Co-operation given by all the members and other business associates.

**FOR AND ON BEHALF OF BOARD OF DIRECTORS OF
SOCRUS BIO SCIENCES LIMITED**



**MANAGING DIRECTOR
MR. RAJEEV AGNIHOTRI**



**WHOLE TIME DIRECTOR
MRS. MADHVI AGNIHOTRI**

DATE : 05.09.2013

PLACE: MUMBAI (M.H.)

Corporate Governance Report
ENCLOSURE TO THE DIRECTORS REPORT

The detailed report on implementation by the company of the Corporate Governance Code as incorporated in Clause 49 of the Listing Agreement with Stock Exchange is set out below:

1. Corporate Governance Philosophy

The management believes that corporate growth, goals, transparency and enhanced stakeholder value are to be achieved only through good corporate governance.

2. Board of Directors

The Board of Directors of Socrus Bio Sciences Limited (the Company) comprised of Executive Chairman, one executive, non independent whole time director, One Non Executive Non-Independent director and three Non executive independent directors. During the period under review the Board maintained the composition as follows.

The composition and category of the Board of Directors as on March 31, 2013 was as follows:

Category	Name of Director
Chairman and MD (executive non independent)	Mr. Rajeev Agnihotri
Whole time director (Executive Non independent)	Mrs. Madhvi Agnihotri
Non Executive non Independent Directors	Mr. Ashwani Kumar Trivedi
Non executive independent Directors	Mr. Sunil Kumar Jain Mr. Sanjay Kumar Upadhyay Mr. Manish Jain

There has not been any change amongst the composition of board of the company during the financial year.

The Board of Directors met 7 (Seven) times during the period under review on 14th May 2012, 14th August 2012, 2nd September, 2012; 12th November, 2012; 14th January 2013 and 31.03.2013. The Attendance of each Director at the meeting of the Board of Director held during the year and the last Annual General Meeting and also the number of Board of Directors is as under:

Name of Director	Appointment (A) Resignation (R) Date	Attendance Particulars		No of Directorships in domestic public limited companies (including this Company)		No of Committee Memberships* in domestic public limited companies (including this company)	
		Board Meetings	Last AGM	As Chairman	As Director	As Chairman	As Member
Mr. Rajeev Agnihotri	A 26.11.2007	7	Yes	2	2	2	2
Mrs. Madhvi Agnihotri	A 18.12.2007	7	Yes	-	4	-	2
Mr. Ashwani Kumar Trivedi	A 18.12.2007 R 25.04.2013	7	Yes	-	2	-	-
Mr. Sunil Kumar Jain	A 07.07.2009	7	Yes	-	3	-	3
Mr. Manish Jain	A 07.07.2009	7	Yes	-	1	-	3
Mr. Sanjay Kumar Upadhyay	A 07.07.2009	7	Yes	-	3	2	2

None of the directors is a member of more than ten committees or acting as Chairman of more than five committees across all companies in which he is a director.

3. Audit Committee

The Company has complied with the requirements of Clause 49 of the Listing Agreement and section 292 A of the Companies Act, 1956 relating to the composition and terms of reference of the Audit Committee.

Following changes took place in the constitution of Audit Committee during the year:

There has not been any change in the composition of the Audit committee since its reconstitution on 07.07.2009. The Committee comprised of 1 (One) Independent non Executive Director as chairman (Mr. Sanjay Kumar Upadhyaya), 2 (Two) independent non Executive Directors (Mr. Sunil Kumar Jain and Mr. Manish Jain) and 1(One) Executive non Independent director (Mr. Rajeev Agnihotri).

The responsibilities of the Audit Committee include financial reporting, standards compliances and review financial policies of the Company and also to recommend the appointment of Statutory Auditors and Internal Auditors and to fix their fees. The Audit Committee evaluates audit policies, plans and procedures and reviews other functions through various internal audit reports. The committee also reviews all the unaudited and audited financial results before the submission to the Board. The Audit Committee met 4 (Four) times during the year. The members of the Audit Committee and their attendance are given below:

Name of the Member	During the financial year	
	No. of meetings attended	Whether attended AGM
Mr. Rajeev Agnihotri	4	Yes
Mr. Sunil Kumar Jain	4	Yes
Mr. Manish Jain	4	Yes
Mr. Sanjay Kumar Upadhyay (chairman after 07.07.2009)	4	Yes

Representative of the Statutory Auditors are invited to attend the meetings.

4. Remuneration Committee

Following changes took place in the constitution of Remuneration Committee during the year:

There has not been any change in the Composition of the Remuneration committee since its reconstitution (on 07.07.2009). the Committee comprised of 1 (One) Independent non Executive Director as chairman (Mr. Sanjay Kumar Upadhyay) and 2 (Two) independent non Executive Directors (Mr. Sunil Kumar Jain and Mr. Manish Jain).

As there is no remuneration being provided to executive director hence no remuneration committee meeting was held during the year. The company pays no sitting fees to any director for attending Board/Committee meeting.

5. Shareholders/ Investors Grievances Committee

Following changes took place in the constitution of Shareholders/Investors Grievances Committee during the year:

There has not been any change in the Composition of the Shareholders Grievance Committee since its reconstitution (on 07.07.2009). The Committee comprised of 1 (One) Executive Director as chairman (Mr. Rajeev Agnihotri,) and 2 (Two) independent non Executive Directors as its members(Mr. Sunil Kumar Jain and Mr. Manish Jain)

The committee apart from the ensuring timely share transfers also looks into any investors complaints. The committee has designated Compliance Officer as the officer in-charge of all investor complaints. The matters unresolved for more than 15 days are reported to the committee. The committee met three times during the year. The attendance of the committee is as under:

Name of the Member	During the financial year	
	No. of meetings attended	Whether attended AGM
Mr. Rajeev Agnihotri (Chairman)	3	Yes
Mr. Sunil Kumar Jain	3	Yes
Mr. Manish Jain	3	Yes

6. Code of Conduct

As required by the amended Clause 49 of the Listing Agreement, the Board of Directors of the Company has adopted a Code of Conduct for all Board Members and Management of the Company. The members of the Board and Senior Management of the Company have affirmed compliance of the said Code of Conduct during the year under review.

7. Disclosure

a. Disclosures on materially significant related party transactions that may have potential conflict with the interest of the Company at large

As required by the amended Clause 49, a statement in summary form of transaction with related parties are being periodically placed before the audit committee. There were transactions of the Company of non material significance with its Promoters, Directors or the Management or Relatives during the year, which may not have any potential conflict with the interest of the Company at large. Transactions with related parties as per the requirements of Accounting Standard (AS-18) i.e. 'Related Party Disclosures' if any, disclosed in the Notes to the Accounts for the financial year.

b. Disclosure of Accounting Treatment

In the preparation of the financial statements, the company has followed the Accounting Standards referred to in the Companies Act, 1956. The significant accounting policies which are consistently applied are set out in the Annexure to the Notes to the Accounts.

c. Risk Management

The Company has laid down the procedures to inform the Board members about the risk assessment and minimization procedures of the material and they are being reviewed periodically.

d. Details of non-compliance by the Company, Penalties & Strictures imposed on the Company by Stock Exchanges or SEBI or any statutory authority, on any matter related to capital markets, during the last three years

The Company has complied with the requirements of the Listing Agreements entered into with the Bombay Stock Exchange (BSE) as well as the regulations and guidelines of the SEBI. No penalties imposed by either SEBI or the Stock Exchanges or any statutory authority for non compliance of any matter related to the capital markets. The shares of the company are traded in the stock exchange. Listing fee has been payable by the company to the stock exchange and shall be paid shortly.

8. Annual General Meetings (AGM)

The details of last three Annual General Meetings are as under:

Year	Venue	Day/Date	Time
20 th	Hotel Solitaire, Near International & Domestic Airport, Opp. APT Colony, New Sanjay Nagar, Sahar Road, Chakala, Andheri (East), Mumbai-99	29.09.2010	11.00 a.m
21 st	Hotel Solitaire, Near International & Domestic Airport, Opp. APT Colony, New Sanjay Nagar, Sahar Road, Chakala, Andheri (East), Mumbai-99	30.09.2011	11.00 a.m
22 nd	Hotel Solitaire, Near International & Domestic Airport, Opp. APT Colony, New Sanjay Nagar, Sahar Road, Chakala, Andheri (East), Mumbai-99	28.09.2012	11.00a.m

9. Means of Communications

The Company has promptly reported all information including declaration of Quarterly Un audited financial Results and Audited Results to the stock exchange where the security of company is listed and also the company has published the un-audited financial results in the English Newspapers and Marathi news papers.

10. General Shareholders Information

Registered Office: 30, 16-A, PMGP Colony, Manacle Cave Road, Andheri (E), Mumbai-400093

Annual General Meeting: The 23rd Annual General Meeting of the company will be held on Monday, the 30th day of September, 2013 at Hotel Solitaire, Near International & Domestic Airport, Opp. APT Colony, New Sanjay Nagar, Sahar Road, Chakala, Andheri (East), Mumbai-99 (being a place within the local limits of the city where the registered office of the company is situated at present) at 11.00 a.m.

Financial Year: 01st April to 31st March, every year

Date of Book Closure: 27th September 2013 to 30th September 2013 (both days inclusive)

Dividend Payment Date: No dividend for the year hence Not Applicable

Listing on Stock Exchanges: Bombay Stock Exchange Mumbai

Listing Fees: The company has yet to pay the annual listing fees to the Bombay Stock Exchange Limited.

Compliance officer Mr. Rajiv Agnihotri Tele(022) 22906876 Fax : (022) 22906876

Stock Code BSE CODE 524719

Demat ISIN Numbers in NSDL & CDSL INE 858AO1039 FOR NSDL
INE 858AO1039 FOR CDSL

Market Price Data:

Month	Open Price	High Price	Low Price	Close Price
Apr 12	5.00	5.75	4.73	5.00
May 12	4.76	5.00	3.86	4.85
Jun 12	4.90	4.90	3.86	3.96
Jul 12	4.15	4.39	3.80	4.02
Aug 12	3.83	4.23	3.60	3.77
Sep 12	3.61	4.24	3.50	3.81
Oct 12	3.76	4.10	3.40	3.40
Nov 12	3.24	3.46	2.68	2.68
Dec 12	2.55	3.19	2.43	2.58
Jan 13	2.68	2.75	1.80	1.98
Feb 13	2.00	2.27	1.51	1.55
Mar 13	1.60	1.78	1.08	1.18

Registrar & Transfer Agent: Bigshare Services Private Limited
E/2, Ansa, Industrial Estate, Saki Vihar Road, Saki Naka, Andheri
(East), Mumbai 400072.

During the year under review, the Company received complaints from the shareholders as follows. To the best of knowledge of the Company, these complaints were solved to the satisfaction of the shareholders:

Nature of complaints	2012-13		2011-12	
	Received	Attended to	Received	Attended to
Non-receipt of share certificates	7	7	Nil	Nil

Distribution of Shareholding

As on March 31, 2013 the distribution of the equity shareholding of the Company was as follows:

REHOLDING OF NOMINAL RS	Rs.	NUMBE ROF SHAREHOLDERS	PERCENTAGE OF TOTAL	SHARE AMOUNT RS	PERCENTA GE OF TOTAL
1	5000	6702	74.7824	11720010	3.6622
5001	10000	934	10.4218	8415480	2.6296
10001	20000	529	5.9027	875100	2.7342
20001	30000	204	2.2763	5467920	1.7086
30001	40000	97	1.0823	3593300	1.1228
40001	50000	137	1.5287	6621470	2.0690
50001	100000	163	1.8188	12764820	3.9887
100001	999999999	196	2.1870	262693900	82.0849
TOTAL		8962		320027000	100.00

11. Dematerialization of Shares :

Trading in Equity Shares of the company is permitted only in dematerialized form.

12. Outstanding Convertible Instruments:

As on date, the Company has no outstanding convertible instruments.


13. Secretarial Audit For Reconciliation of Capital:

As stipulated by SEBI, a qualified Practising Company Secretary carries out Secretarial Audit. This audit is carried out every quarter. The audit confirms that the total listed and paid-up capital is in agreement with the aggregate of the total shares held in physical form.

14. Declaration

All Board Members, for the year ended 31st March, 2013 affirmed compliance with the Code of Conduct as for as possible, as laid down by the Board of Directors in terms of Clause 49 of the Listing Agreement entered into with the Stock Exchanges.

FOR SOCRUS BIO SCIENCES LIMITED



Mr. Rajeev Agnihotri
Managing Director

Place: Mumbai

Date: 05.09.2013

Management Discussion and Analysis Report

Your Directors are pleased to present the Management Discussion and Analysis Report for the year ended 31st March 2013.

The management discussion and analysis have included in consonance with the code of Corporate governance as approved by the securities Board of India (SEBI). Investors are cautioned that these discussions contain certain forward looking statements that involve Risk and uncertainties including those risks which are inherent in the company's growth and Strategy. The company undertakes no obligation to publicly update or revise any of the opinions or forward looking statements expressed in this report consequent to new information or developments, events or otherwise.

The Management of the company is presenting herein the overview, opportunities and threats, initiatives by the company and overall strategy of the company and its outlook for the future. This outlook is based on management's own assessment and it may vary due to future economic and other future developments in the country

OVERVIEW

The operations of the company are centered on pharma business, finance & investments and media activities. The company deals in trading of major items like caustic soda, penta, Amino Compound and Thelic Anhydride and also software products like software for Accounting in Health insurance, software for gymnasium for bodybuilding, software for programme for Beauty and skin care, etc. the company is also involved in TV channel viz CARE TV.

INDUSTRY STRUCTURE AND DEVELOPMENT

The Indian Media industry is a subject of national pride, interest and media hype. There has been tremendous growth in the media industry of late which can be attributable primarily by an increase in television viewer ship and improved realizations from television subscriptions and film exhibition. Due to some inherent problems the company presently not in comfort with actual media business. The company deals in sale of software, which are procured from outside Agencies which are used by consumers.

There has been tremendous growth in pharma industries also in India for the past few decades. It has a major share in the Indian economy as played by the Indian pharmaceutical industries. Under the pharmaceuticals division, the company deals in wholesale trading of chemicals, which are meant for industrial usage. Laboratories use mainly these chemicals.

Coming to the finance industry where the company is also involved, major developments have taken place for the past few decades in view of the fact that plethora of finance companies have come into existence with various finance products.

And there has been tremendous finance growth due to foreign collaboration, foreign equity participation etc. under finance division, trading in equity shares and stock is the main activity of the company as well as other financing activities.

OPPORTUNITIES AND THREATS:

1. There is a scope to become part of a larger group of larger group of satellite television channels due to diversification in media division
2. Several model of revenue can be improvised by expanding the business activities of the company.
3. Strong bonding with health industries.
4. One of the main businesses being in the finance related areas the company is exposed to credit risks which are inherent to type of business.
5. The company since involved in trading in software business for a very long time there are good prospects for expanding the further activities in this direction.
6. The company is also facing severe competition from other financial companies and software companies

INITIATIVES BY THE COMPANY

The company has taken following initiatives:

1. The efforts are on to reduce the transportation cost on purchasing activities.
2. Every effort is being made to locate new client base to boost software sales.
3. The company is endeavoring to penetrate into newer financial activities.

OUTLOOK

- The company is mainly engaged in finance and business and software business. The company is planning to expand and diversify the activities in the line and E-Cinema to top higher revenues.
- Further, the company is also contemplating to usher in new areas of development in financial activities. The Board of Directors of the company envisaging to augment the investment base of the company through participation in various equity debt, bond market and mutual funds with a view to earn good returns to the company

RISK AND CONCERNS

Due to stiff competitions in the software / finance field where the companies activities are centered on, the overall margins are under pressure.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

The company has a strong Management audit framework. The Audit committee of Promoters directors & Independent Directors. The Audit committee meets every quarter to review compliances which are as under:

- Compliance of the company with applicable statutes, policies – procedures, listing requirements and management guidelines.
- All transactions are being accurately recorded and verified.
- Adherence to applicable accounting standards and policies.

HUMAN RESOURCES / INDUSTRY RELATIONS

- The company provides excellent working environment so that the individual staff can reach his/her full potential.
- The company is poised to take on the challenges and March towards accomplishing its mission with success.

CAUTIONARY STATEMENT

Statement in the Management Discussion and analysis describing the Company's objectives, expectations or predictions may be forward looking within the meaning of applicable securities, laws and regulations. Actual results may differ materially from those expressed in the statement. Several factors could make significant difference to the company's operation. These include climatic conditions and economic conditions affecting demand and supply, government regulations and taxation, natural calamities etc. over which the company does not have any control.

**ANNEXURE-2
ENCLOSURE TO THE DIRECTORS REPORT**

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNING AND OUTGO

Information pursuant to section 217(1)(e) of Companies Act, 1956 read with the Companies (Disclosure of particulars in the report of Directors) Rules, 1988 forming part of Directors' Report.

A) CONSERVATION OF ENERGY

- (i) energy conservation measures taken:
(ii) additional investment and proposals, if any, being implemented for reduction of consumption of energy:

(iii) POWER & FUEL CONSUMPTION:	<u>2012-2013</u>	<u>2011-2012</u>
i. Electricity		
a) Purchased Unit	7045	8091
Total amount	54250	48550.00
Rate/Unit(Rs)	7.70/-	6/-
b) Own Generation (Through Generator)		
Unit(KWH)		
Unit/Ltr of diesel oil	1802	2598
Cost/Unit(Rs)	53	45
ii Coal		
Purchased quantity (in Qtls)	N/A	N/A
Total amount(Rs. In lacs)		
Rate/Unit(Rs)		
iii Furance Oil		
	N/A	N/A
iv. Others		
a)Quantity (in Qtl)	N/A	N/A
b)Amount (Rs. In lacs)		
c)Rate/Unit(In Rs.)		

B) TECHNOLOGY ABSORPTION

I) RESEARCH & DEVELOPMENT:

- a) Specific areas in which R&D carried out by the company:
b) Benefits derived as a result of the above R&D:
c) Expenditure on R&D:
i) Capital
ii) Recurring

- iii) Total
- iv) Total R&D expenditure as a %age of turnover

II) TECHNOLOGY ABSORPTION, ADAPTATION AND INNOVATION:

Detail of technology imported during the past 5 years:

- a) Details of technology imported :
- b) Year of import :
- c) Has technology been imported fully absorbed :
- e) If not fully absorbed, areas where this has not taken place :

C] FOREIGN EXCHANGE EARNINGS AND OUTGO: 2012-2013 2011-2012

FOREIGN EXCHANGE EARNING

FOREIGN EXCHANGE OUTGO

FOR SOCRUS BIO SCIENCES LIMITED



**Mr. Rajeev Agnihotri
Managing Director
Place: Mumbai
Date: 05.09.2013**

Ref. No.

Date.....

CORPORATE GOVERNANCE COMPLIANCE CERTIFICATE

To The Members of
SOCRUS BIO SCIENCES LIMITED

We have examined the compliance of conditions of Corporate Governance by **SOCRUS BIO SCIENCES LIMITED** for the year ended on 31st March, 2013, as stipulated in clause 49 of the Listing Agreement of the said company with stock exchanges in India.

The compliance of conditions of Corporate Governance is the responsibility of the management.

Our examination was limited to procedures and implementation thereof, adopted by the company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the company.

In our opinion and to the best of our information and according to the explanations given to us, we certify that the company has complied with the conditions of Corporate Governance as stipulated in the above-mentioned Listing Agreement except for the appointment of Whole time Company Secretary as required under section 383A of the Companies Act, 1956.

We further state that such compliance is neither an assurance as to the future viability of the company nor the efficiency or effectiveness with which the management has conducted the affairs of the company

Place: Indore
Date:05/09/2013

Yours Faithfully,
For M/s Shyam Nagori & Company
Chartered Accountants


FRN-004573C



(CA Shyam Nagori)

Proprietor

M. No. 073609



SOCRUS BIO SCIENCES LIMITED

Registered Office:
30, 16-A PMGP COLONY, MAHAKALI CAVE ROAD, ANDHERI(E), MUMBAI
ANNUAL GENERAL MEETING- SEPTEMBER 30, 2013 AT 11.00 A.M.

DP Id.	
Client Id/ Folio No.	
No. of shares	

NAME & ADDRESS OF THE REGISTERED SHAREHOLDER
--

I certify that I am a registered Shareholder/proxy for the registered shareholder of the Company.

Whereby record my presence at the ANNUAL GENERAL MEETING of the Company at Hotel Solitaire, Near International & Domestic Airport, Opp. APT Colony, New Sanjay Nagar, Sahar Road, Chakala, Andheri (E), Mumbai-99 on Monday, September 30, 2013.

SIGNATURE

Note: Please complete it and hand it over at the entrance of the hall.

SOCRUS BIO SCIENCES LIMITED

Registered Office:
30, 16-A PMGP COLONY, MAHAKALI CAVE ROAD, ANDHERI(E), MUMBAI
ANNUAL GENERAL MEETING- SEPTEMBER 30, 2013 AT 11.00 A.M.

I/We
Ofin the district ofbeing a member/members of
SOCRUS BIO SCIENCES LIMITED hereby appoint.....
Of.....in the district of.....or failing him
.....of.....in the district of.....

As my/our proxy to vote for me/us on my/our behalf at the ANNUAL GENERAL MEETING of the company, to be held on Monday, **September 30, 2013** and at my adjournment thereof.

Signed this.....day of.....2013

DP Id.	
Client Id/ Folio No.	
No. of shares	

Affix a
15 paise
revenue
stamp

Signature.....

Note: This form of proxy in order to be effective should be duly completed and deposited at the registered office of the Company, not less than 48 hours before the commencement of the Meeting.

SOCRUS BIOSCIENCES LIMITED
(Formerly Known as Tanu Health Care Limited)

23th ANNUAL REPORT
FINANCIAL YEAR 2012-13

REG OFF: 30-16-A, PMGP COLONY
MAHAKALI CAVE ROAD, ANDHERI (E),
MUMBAI

INDEPENDENT AUDITORS REPORT

0

THE MEMBERS OF**M/S SOCRUS BIO SCIENCES LIMITED**

Report on the Financial Statements

We have audited the accompanying financial statements of M/s Socrus Bio Sciences Limited ("the Company"), which comprise the Balance Sheet as at 31st March, 2013, the Statement of Profit and Loss and the Cash Flow Statement for the year then ended, and a summary of the significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Management is responsible for the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the Accounting Standards referred to in sub-section (3C) of section 211 of the Companies Act, 1956 ("the Act"). This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with the ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers the internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

- (a) in the case of the Balance Sheet, of the state of affairs of the Company as at 31st March, 2013;
- (b) in the case of the Statement of Profit and Loss, of the Loss of the Company for the year ended on that date, and
- (c) in the case of the Cash Flow Statement, of the cash flows of the Company for the year ended on that date.



Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditor's Report) Order, 2003("the Order") issued by the Central Government of India in terms of sub-section (4A) of section 227 of the Act, we give in the Annexure a statement on the matters specified in paragraphs 4 and 5 of the Order.

As required by Section 227(3) of the Act, we report that:

- a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c) The Balance Sheet, Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- d) In our opinion, the Balance Sheet, Statement of Profit and Loss, and the Cash Flow Statement comply with the Accounting Standards referred to in sub-section (3C) of section 211 of the Act.
- e) On the basis of the written representations received from the directors as on 31st March, 2013 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2013 from being appointed as a director in terms of clause (g) of sub-section (1) of section 274 of the Act.
- g) Since the Central Government has not issued any notification as to the rate at which the cess is to be paid under section 441A of the Companies Act, 1956 nor has it issued any Rules under the said section, prescribing the manner in which such cess is to be paid, no cess is due and payable by the Company.


PLACE-INDORE

DATE- 05th SEP 2013

FOR: SHYAM NAGORI & COMPANY

CHARTERED ACCOUNTANTS

FRN-004573C


(SHYAM NAGORI)

PROPRIETOR


M. NO. 073609



ANNEXURE TO THE AUDITORS REPORT

Referred to in paragraph (1) of our report of even date attached

- I) (a) In our opinion and according to information and explanations given to us. The company has maintained proper records showing full particulars including quantitative details and situation of its fixed assets.
- (b) According to the information and explanations given to us the fixed assets of the company have been physically verified by the Management at reasonable intervals during the year and no material discrepancies are stated to have been noticed on such verification as compared to Books of Account.
- (c) In our opinion and according to information and explanations given to us, all fixed assets have been disposed off during the year, which could not affect the going concern status of the Company.
- II) (a) According to the information and explanations given to us. Physical verification of inventory has been conducted at reasonable intervals by the Management during the year. In our opinion, the frequency of verification is reasonable.
- (b) In our opinion and according to information and explanation given to us, the procedures of physical verification of inventory followed by the Management are reasonable and adequate in relation to the size of the company and the nature of its business.
- (c) In our opinion, the company has maintained proper records of inventory and according to information and explanations given to us no material discrepancies were noticed on physical verification conducted by the management.
- III) (a) In our opinion and according to information and explanations given to us, the Company has granted loans to three parties covered in the Register maintained under section 301 of the Companies Act 1956, the maximum amount involved during the year was Rs.3500000/- and year end balance is Rs. 3500000/-
- (b) The rate of Interest and other terms and conditions of loans given by the company, to the extent of interest free loans are not prejudicial to the interest of the company.
- (c) The parties are regular in repaying principal as stipulated and have been regular in payment of interest, if any.
- (d) There is no overdue amount of loans granted to companies, firms or other parties listed in the register maintained under section 301 of the companies act, 1956.
- (e) The company has not taken unsecured loans covered in the register maintained under section 301 of the Companies Act 1956, hence point (f) and (g) is not applicable to the Company.
- IV) In our opinion and according to the information and explanations given to us, there are adequate internal control procedures commensurate with the size of the company and nature of its business for the purchase of inventory and fixed assets and for the sale of goods services. During the course of our audit, we have not observed any continuing failure to correct major weakness in internal controls.
- V) (a) According to the information and explanations given to us, we are of the opinion that the transaction that needs to be entered into the register maintained under section 301 of the companies Act. 1956 have been so entered.
- (b) In our opinion and according to the information and explanations given to us, the transactions made in pursuance of contracts of arrangements entered in the register maintained under section 301 of the Companies Act. 1956 have been made at prices which are reasonable having regard to prevailing market prices at the relevant time.
- VI) According to the information and explanations given to us, the company has not accepted deposits during the year and consequently the provisions of Section 58 A and 58 AA of the Companies Act and the Rules framed there under are not applicable.
- VII) We are of the opinion that the company has an internal audit system commensurate with the size company and nature of its business.



- VIII) In our opinion and according to information and explanations given to us, the maintains of the cost records have been prescribed by the Central Government under Section 209 (1) (d) of the Companies Act. 1956. for the activities of the company and we have however not made a detailed examination of the cost records with a view to determine whether they are accurate or complete. We have been explained that the cost audit will be done by the company in due course.
- (X) (a) According to the information and explanation given to us, the company is regular in depositing with appropriate authorities undisputed statutory Dues including provident fund employees' state insurance, income tax, wealth tax, sales tax, excise duty, cess and other material statutory dues applicable to it.
- (b) According to the information and explanations given to us, no undisputed statutory dues were in arrears as at 31.03.2013 for a period of more than six months from the date they become payable.
- (c) According to the information and explanations given to us, there were no pending dues which have not been deposited on account of any dispute in respect of sales tax / income tax / custom duty / wealth tax / excise duty / cess as at 31 st March 2013
- X) The company have accumulated losses as at 31st st March 2013. The company have incurred cash losses during the financial year covered under audit but incurred profit in the immediately preceding financial year.
- XI) In our opinion according to the information and explanations given to us, the company does not have any outstanding dues to financial institutions, banks or debentureholders.
- XII) According to the information and explanations given to us, the company has not granted any loans and advances on the basis to security by way of pledge of shares, debentures and other securities, hence the maintenance of adequate documents and records is not applicable.
- XIII) In our opinion and according to the information and explanations provided to us, the nature of activities of the company does not attract any special statute applicable to chit fund and a Nidhi / Mutual Benefit fund / Society.
- XIV) According to information and explanation given to us, the company has maintained proper records for dealing in shares & debentures and timely entries have been made therein, all shares, debentures and other securities have been held by the company in its own name.
- XV) According to the information and explanations given to us, the company has not given any guarantee for loans taken by other, from Bank of Financial institution.
- XVI) The Company has not accepted any term loans during the year.
- XVII) According to the information and explanations given to us and on an overall examination of the balance sheet of the company, we are of the opinion that the no funds raised on short - term basis have been used for long - term investment. No long -term funds have been used to finance short -term assets except permanent working capital.
- XVIII) In our opinion and according to the information and explanations given to us, the company has not made any preferential allotment of shares during the financial year to parties and companies covered in Register maintained under section 301 of the Act.
- X) The Company has not issued any debentures, hence the provisions of clause 4 (xix) are not Applicable to the company.
- XX) During the financial year, company has not raised any money by public issues.
- XXI) In our opinion and according to the information and explanations given to us, no fraud on or by the company was noticed or reported during the year.

PLACE - INDORE

DATE - 05th September 2013


For: SHYAM NAGORI & COMPANY
CHARTERED ACCOUNTANTS

FRN-004573C


(SHYAMNAGORI)

PROPRIETOR

M. No. 073609




SOCRUS BIOSCIENCES LIMITED
BALANCE SHEET AS AT 31ST MARCH 2013

(Amount in Rs.)

Particulars	Note No.	Year Ended on	Year Ended on
		31.03.2013	31.03.2012
I EQUITY AND LIABILITIES			
1 Shareholders' Funds			
(a) Share Capital	1	320027000	320027000
(b) Reserves and Surplus	2	-307281381	86340795
2 Non-Current Liabilities			
(a) Other Long Term Liabilities		0	0
(b) Long Term Provisions		0	0
3 Current Liabilities			
(a) Trade Payables	3	9645557	564550
(b) Short-Term Provisions	4	45000	35500
TOTAL		22436176	406967845
II ASSETS			
1 Non-Current Assets			
(a) Fixed Assets	5		
(i) Tangible Assets		0	183573007
(ii) Intangible assets		0	43182359
(b) Long-Term Loans and Advances	6	3577732	14555732
(c) Deferred tax assets		6297956	6297956
2 Current Assets			
(a) Inventories	7	9050000	60630330
(b) Trade Receivables	8	0	68233557
(c) Cash and Cash Equivalents	9	97822	546526
(b) Short-Term Loans and Advances	6	3400156	29910293
(e) Other Current Assets	10	12510	38085
TOTAL		22436176	406967845

GNIFICANT ACCOUNTING POLICIES AND NOTE
FORMING PART OF THE ACCOUNTS
AS PER OUR REPORT OF EVEN DATE

FOR SHYAM NAGORI & COMPANY
Chartered Accountants
FRN : 004573C



(SHYAM NAGORI)
Membership no. 073609
PLACE : INDORE
DATE : 05.09.2013



FOR AND ON BEHALF OF THE BOARD


DIRECTOR


DIRECTOR


SOCRUS BIOSCIENCES LIMITED

STATEMENT OF PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31ST MARCH 2013

Particulars	Note No.	Year Ended on	Year Ended on
		31.03.2013	31.03.2012
I Revenue from Operations	11		
Pharma sales		31050000	0
biotech sales		167825600	301600150
Other Income		0	398200
		198875600	301998350
II Expenses			
Material Purchases-Pharma	12	66075650	0
- Biotech Purchases		215090190	274650313
changes in inventory of biotech	13	40579760	-40579760
changes in inventory	13	11000570	1000200
Employee benefit Expense	14	950000	1120000
Finance costs	15	15070	20150
Depreciation and amortization Expense	5	43182359	494904
Other Expenses	16	64631170	742173
Loss on sale of assets		150973007	0
Total Expenses		592497776	237447980
III Profit before exceptional and extraordinary items and Tax (I-II)		-393622176	64550370
IV Profit from Biotechnology		-87844350	65152370
V Profit before tax		-305777826	-602000
VI Tax Expense			
(1) Provision for Income Tax		0	0
VII Add: Profit from Biotechnology		-87844350	65152370
VIII Profit/Loss for the year from continuing Operations (VI-VIII)		-393622176	64550370
Less: Deferred Tax liabilities			13336821
IX Profit/Loss from discontinuing operations		0	0
X Tax expense of discontinuing operations		0	0
XI Profit/(loss) from discontinuing operations(after tax)(IX-X)		0	0
XII Profit / (Loss) for the period (VIII + XI)		-393622176	51213549
XIII Earnings per quity share			
(1) Basic		0	1.60
X (2) Diluted		0	1.60

SIGNIFICANT ACCOUNTING POLICIES AND NOTE FORMING PART OF THE ACCOUNTS AS PER OUR REPORT OF EVEN DATE FOR SHYAM NAGORI & COMPANY Chartered Accountants
FRN : 04573C

(SHYAM NAGORI)
Membership no. 073609
PLACE : INDORE
DATE : 05.09.2013



FOR AND ON BEHALF OF THE BOARD

[Signature]
DIRECTOR

[Signature]
DIRECTOR

SOCRUS BIOSCIENCES LIMITED

Share Capital	As at 31 March 2013		As at 31 March 2012	
	Number	Amount	Number	Amount
<u>Authorised</u>				
3,20,10,000 Equity Share of Rs. 10/- each (Previous Year 3,20,00,000 equity share of Rs. 10/- each)	32,010,000	320,100,000	32,010,000	320,100,000
<u>Issued Subscribed & fully Paid up</u>	32,002,700	320,027,000	32,002,700	320,027,000
3,20,02,700 Equity Share of Rs. 10/- each (Previous Year 32002700 equity Share of Rs. 10/- each)				

Particulars	Equity Shares			
	As at 31 March 2013		As at 31 March 2012	
	Number	Amount	Number	Amount
<u>Shares outstanding at the beginning of the year</u>	32002700	320027000	32002700	320027000
<u>Shares Issued during the year</u>				
<u>Shares bought back during the year</u>				
<u>any other movement (Please sepecify)</u>				
<u>Shares outstanding at the end of the year</u>	32002700	320027000	32002700	320027000

Below are the name of the shareholders holding more than 5% of Shares

Name	Category	Class of Share	No. of Share Holding	Percentage of Holding
Rajeev Agnihotri	Director	Equity Share	10011790	31.2842
Bharat Bio Remedies	Corporate bodies	Equity Share	1725000	5.3902
Healthcare venture partners	Corporate bodies	Equity Share	1675000	5.2339



SOCRUS BIOSCIENCES LIMITED

Note -02


RESERVE & SURPLUS	As at 31 March 2013	As at 31 March 2012
(a) Surplus		
Opening Balance	86340795	35127246
(+) Net Profit for the year	-393622176	51213549
Closing Balance	-307281381	86340795

Note - 3

TRADE PAYABLES	As at 31 March 2013	As at 31 March 2012
Trade Payable		
for supplies & services	9596096	564550
Big Share Service Pvt.Ltd.	49461	0
TOTAL	9645557	564550

Note - 4

SHORT TERM PROVISIONS	As at 31 March 2013	As at 31 March 2012
(a) Provision		
(i) Provision for Audit Fees	40000	30000
(ii) Consultancy Payable	5000	5500
TOTAL	45000	35500

For Socrus Bio Sciences Ltd.

Director


For Socrus Bio Sciences Ltd.



Director



Fixed Assets		Gross Block					Accumulated Depreciation					Net Block	
		Balance as at 1 April 2012	Additions/(Deposals)	Acquired Through business combinations	SALES/DEDUCTION	Balance as at 31 March 2013	Balance as at 31 March 2012	Depreciation charge for the year	Adjustment due to revaluation	on disposals	Balance as at 31 March 2013	Balance as at 31 March 2012	
S.No.		Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	
	Tangible Assets	4900000			4900000	0	1666689			1666689	0	4900000	
1	Land	5947371			5947371	0	2200431			2200431	0	4280682	
2	Building	2733473			2733473	0	3250876			3250876	0	533042	
3	Plant & Machinery	3678128			3678128	0	3535639			3535639	0	427252	
4	Electrical Equipment	3535639			3535639	0	91950			91950	0	0	
5	Furniture & Fixture	91950			91950	0	138034			138034	0	32031	
6	Computer	170065			170065	0	10883619			10883619	0	173400000	
7	Air Conditioner	173400000			173400000	0					0	1833573007	
8	Agriculture Land	194456626			194456626	0					0		
	Total	43182359			43182359	43182359	0			43182359	0	43182359	
	INTANGIBLE ASSETS	43182359			43182359	43182359	0			43182359	0	43182359	
9	Goodwill	43182359			43182359	43182359	0			43182359	0	43182359	
	TOTAL	237638985			237638985	237638985	10388715	494904	0	10883619	226755366	227250270	
	GRAND TOTAL	237638985			237638985	237638985	10388715	494904	0	10883619	226755366	227250270	
	Previous Year	237638985			237638985	237638985	10388715	494904	0	10883619	226755366	227250270	

Note-(1) The Agriculture Land was acquired for Rs. 23400000 and loss of Rs. 15000000 has been transferred to profit & loss account
 (2) Other assets of book value of Rs. 10173007 as on 31.03.2012 was sold for Rs. 9200000 and loss for Rs. 973007 was transferred to profit & loss account.
 (3) Goodwill was written off to Profit & Loss account

For Socrus Bio Sciences Ltd.

 Director

For Socrus Bio Sciences Ltd.

 Director



SOCRUS BIOSCIENCES LIMITED

(Amount in Rs.)

Note - 6

<u>LOANS AND ADVANCES</u>	As at 31 March 2013		As at 31 March 2012	
	Rs.	Rs.	Rs.	Rs.
LONG TERM				
1. Loans and advances to related Parties	3500000		3500000	
to others	<u>77732</u>	3577732	<u>11055732</u>	14555732
SHORT TERM				
For supplies & expenses	0		24030211	
staff	45000		52000	
Others	100000		1500000	
for TDS	3255156	3400156	4328082	29910293
TOTAL		6977888		44466025

Note - 07

<u>INVENTORIES</u>	As at 31 March 2013		As at 31 March 2012	
	Rs.	Rs.	Rs.	Rs.
<u>Inventories</u> (As Taken Valued and certified by the Management)				
Shares	9050000		20050570	
Biotech goods	0		40579760	
TOTAL	9050000		60630330	

Note - 08


<u>TREDE RECEIVABLES</u>	As at 31 March 2013		As at 31 March 2012	
	Rs.	Rs.	Rs.	Rs.
Trade receivables (Unsecured & considered good-unless otherwise stated)				
Exceeding Six months	0		66376007	
Others	0		1857550	
TOTAL	0		68233557	

For Socrus Bio Sciences Ltd.

[Signature]
Director

For Socrus Bio Sciences Ltd.

[Signature]
Director



SOCRUS BIOSCIENCES LIMITED

Note - 09

<u>CASH AND CASH EQUIVALENTS</u>	As at 31 March 2013		As at 31 March 2012	
	Rs.	Rs.	Rs.	Rs.
Cash in hand	86465		480986	
Balance with Scheduled bank in current accounts	11357		65540	
TOTAL	97822		546526	

Note - 10


<u>OTHER CURRENT ASSETS</u>	As at 31 March 2013		As at 31 March 2012	
	Rs.	Rs.	Rs.	Rs.
Prepaid Expenses	12510		38085	
TOTAL	12510		38085	

For Socrus Bio Sciences Ltd.

[Signature]
Director

For Socrus Bio Sciences Ltd.

[Signature]
Director



SOCRUS BIOSCIENCES LIMITED

(Amount in Rs.)

Note -11

SALES	As at 31 March 2013	As at 31 March 2012
	Rs.	Rs.
<u>Revenue From Operation</u>		
(a) Pharma Sales	31050000	
(b) Biotech sales	167825600	301600150
(c) Other Income	0	398200
TOTAL	198875600	301998350

Note -12

PURCHASES	As at 31 March 2013	As at 31 March 2012
	Rs.	Rs.
PURCHASES		
(a) Indigenous Pharma Biotech	66075650 215090190	274650313
TOTAL	281165840	274650313

Note - 13

CHANGES IN INVENTORY OF FINISHED GOODS	As at 31 March 2013	As at 31 March 2012
	Rs.	Rs.
Inventories at the end of the year:		
Finished goods	0	40579760
TOTAL	0	40579760
Inventories at the beginning of the year:		
Finished goods	40579760	0
TOTAL	40579760	-40579760

For Socrus Bio Sciences Ltd.

[Signature]
Director

For Socrus Bio Sciences Ltd.

[Signature]
Director



SOCRUS BIOSCIENCES LIMITED

Inventories at the end of the year : shares	9050000	20050570
	9050000	20050570
Inventories at the beginning of the year : shares	20050570	21050770
	20050570	21050770
TOTAL	11000570	1000200
Grand Total	51580330	-39579560

Note -14

EMPLOYEE BENEFIT EXPENSES	As at 31 March 2013	As at 31 March 2012
	Rs.	Rs.
a) Salaries and incentives	950000	1120000
TOTAL	950000	1120000

Note -15

FINANCE COST	As at 31 March 2013	As at 31 March 2012
	Rs.	Rs.
Bank Charges.	15070	20150
TOTAL	15070	20150

For Socrus Bio Sciences Ltd.

[Signature]
Director

For Socrus Bio Sciences Ltd.

[Signature]
Director



SOCRUS BIOSCIENCES LIMITED

Note -16

<u>OTHER EXPENSES</u>	As at 31 March 2013	As at 31 March 2012
	Rs.	Rs.
<u>Other Expenses</u>		
Advertisement Expenses	1826	4412
Auditors Remuneration	45000	35500
Depository Charges-CDSL/NSDL	119130	201886
Electricity Charges	54250	48550
Listing fees	176851	42500
Miscellaneous Expenses	95512	121430
Printing & Stationery	32120	40560
Lease Rent, Rates & Taxes	16004	43200
Share Transfer Charges & demat Charges	37856	70444
Telephone Charges	19421	26541
Travelling Charges	26200	50950
Legal & Professional Fees	7000	56200
Bad debts	64000000	0
TOTAL	64631170	742173
<u>AUDITORS REMUNERATION</u>	As at 31 March 2013	As at 31 March 2012
	Rs.	Rs.
(a) Statutory Audit Fees	30000	25000
(b) Tax audit fees	10000	5000
(c) For other Services	5000	5500
TOTAL	45000	35500

For Socrus Bio Sciences Ltd.

[Signature]
Director

For Socrus Bio Sciences Ltd.

[Signature]
Director




CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2013

Name of the Company- **SOCRUS BIOSCIENCE LIMITED**
 Cash Flow Statement for the year ended 31 March, 2013

PARTICULARS	For the year ended 31 March, 2013		For the year ended 31 March, 2012	
	₹	₹	₹	₹
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax	-393622176.00		64550370.00	
<u>Adjustments for:</u>				
Depreciation and amortisation	43182359		494,904.00	
Loss on sale of assets	150973007			
Operating profit / (loss) before working capital changes		-199466810.00		65045274.00
<u>Changes in working capital:</u>				
<u>Adjustments for (increase) / decrease in operating assets:</u>				
Inventories	51580330		-39579560	
Trade receivables	68233557		-14865353	
Loans and advances	37488137		-11475211	
Other current assets	25575		51346	
<u>Adjustments for increase / (decrease) in operating liabilities:</u>				
Trade payables	9081007		198948	
Other current liabilities	9500		0	
Other long-term liabilities	0		0	
Short-term provisions	0		5500	
		166418106		-65664330.00
Cash flow from extraordinary items		-33048704		-619056.00
Cash generated from operations		-33048704		-619056.00
Net income tax (paid) / refunds		0		0
Net cash flow from / (used in) operating activities (A)		-33048704		-619056.00
B. Cash flow from investing activities				
Sale of fixed assets		32600000		0
Goodwill (intangible assets)		0		0
preliminary expenses paid		0		0
		32600000		0
Net cash flow from / (used in) investing activities (B)				
C. Cash flow from financing activities				
Proceeds from issue of equity shares		0		0
Increase in reserve & surplus		0		0
Long term liability paid		0		0
Cash flow from extraordinary items		0		0
Net cash flow from / (used in) financing activities (C)		0		0
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		-448704.00		-619056.00
Cash and cash equivalents at the beginning of the year		546526.00		1165582.00
Effect of exchange differences on restatement of foreign currency Cash and cash equivalents at the end of the year		97822.00		546526.00
Reconciliation of Cash and cash equivalents with the Balance Sheet:				
Cash and cash equivalents as per Balance Sheet (Refer Note 9)				
Less: Bank balances not considered as Cash and cash equivalents as				
Net Cash and cash equivalents (as defined in AS 3 Cash Flow Statements)				
Add: Current investments considered as part of Cash and cash equivalents				
Cash and cash equivalents at the end of the year *				
* Comprises:				
(a) Cash on hand				
(b) Cheques, drafts on hand				
(c) Balances with banks				
(i) In current accounts				
(ii) In EEFC accounts				
(iii) In deposit accounts with original maturity of less than 3 months				
(iv) In earmarked accounts (give details) (Refer Note (ii) below)				
(d) Others (specify nature)				
(e) Current investments considered as part of Cash and cash equivalents				

Notes:
 (i) The Cash Flow Statement reflects the combined cash flows pertaining to continuing and discounting operations.
 (ii) These earmarked account balances with banks can be utilised only for the specific identified purposes.
 See accompanying notes forming part of the financial statements

In terms of our report attached.
FOR SHYAM NAGORI & COMPANY
 Chartered Accountants
 FBN-004573C

 (SHYAM NAGORI)
 PROPRIETOR
 M. NO. 073609

For and on behalf of the Board of Directors

Director Director

Place: INDORE
 Date: 05/09/2013

For Socrus Bio Sciences Ltd.

For Socrus Bio Sciences Ltd.

SOCRUS BIO SCIENCES LIMITED

(Formerly Known as Tanu Healthcare Limited)

FOR THE YEAR ENDED ON 31/03/2013

SIGNIFICANT ACCOUNTING POLICIES:

1. A. METHOD OF ACCOUNTING

The Financial statements are prepared under the historical cost conventions using the accrual method of accounting unless otherwise hereinafter. Accounting policies not referred otherwise are consistent with the normally accepted accounting principles.

B. REVENUE RECOGNITION

All Income and Expenditure are accounted for on accrual basis. Dividend income is recognised as and when received.

2. FIXED ASSETS AND DEPRECIATION

I. All fixed assets are stated of cost of acquisition or construction less accumulated depreciation (except free hold land). Cost includes cost of acquisition and installation/construction, other direct expenses and allocated preoperative expenses, Depreciation of fixed assets has been provided on straight/line method in the manner specified in schedule XIV to the companies Act 1956.

II. Depreciation on fixed assets added/disposed off during the year is provided on pro rata basis.

3. BORROWING COST

Borrowing costs attributable to the acquisition and construction of qualifying assets are capitalized as part of the cost of such asset upto the date when such asset is ready for its intended use. Other borrowing costs are charged to profit & Loss a/c.

4. INVESTMENT

Investments held by company are long term nature, which carries at cost. Provision against diminution in value of investments has been made in case diminution is considered as other than temporary as per the criteria laid down by the board of director, after considering that such investment are if strategic in nature, however unquoted share are valued at cost only.

5. VALUATION OF INVENTORIES

A. Trading goods are Valued at cost or net realizable value whichever is lower.

B. Finished goods are valued at cost or net realizable value whichever is lower

C. Unquoted shares are valued at Cost.

D. Quoted shares are valued at cost or net realizable value whichever is less.

Cost for the above purpose is ascertained on FIFO method.

6. TAXES ON INCOME

Current tax is the amount of tax payable on the taxable income for the year as determined in accordance with the provisions of the income tax act, 1961. Deferred tax is recognized on timing differences. Being the difference between taxable income & accounting income that originate in one period and are capable of reversal in one or more subsequent period. Deferred tax assets are recognized and carried forward only if there is a reasonable/virtual certainty of realization.

For Socrus Bio Sciences Ltd.

Director



For Socrus Bio Sciences Ltd.

Director

7. RETIREMENT BENEFITS

Gratuity shall be accounted for as and when the company statutorily become liable.

8. FOREIGN EXCHANGE TRANSACTIONS

Foreign currency transactions are recorded at the exchange rate prevalent as on the date of the transaction. Any exchange gains or losses arising out of the subsequent fluctuations are accounted for in the profit & loss account except those relating to acquisition of fixed assets, which are adjusted to the cost of the assets.

9. USE OF ESTIMATES

The presentation of financial statements in conformity with the generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affects the reported amounts of assets and liabilities and disclosures of contingent liabilities on the date of financial statements and reported amounts of revenue and expenses for that year. Although these estimates are based upon managements best knowledge of current events and actions, actual results could differ from these estimates.

- 10 In the absence of any information provided to us about the status of company, we are unable to report an amount outstanding and due for more than 30 days in excess of Rs. 1.00 lacs to Small Scale Undertaking as desired vide notification dated 22.02.1999 in the gazette of India by the department of company law affairs Ministry of law Justice and company affairs, Govt of India.

NOTES TO THE ACCOUNTS

01. CONTINGENT LIABILITIES :

A. The contingent liabilities may exist in respect of pending assessment with income tax, sales tax, excise duty etc, where the amounts are not ascertainable.

B. The Company has not provided a liability of Rs. 1940050 on account of penalty u/s 271 E of the IT act 1961, for the A.Y. 2001-02 and the company is preferring a appeal in ITAT (APPEAL) for waiver of same.

C. An appeal preferred by the company for A.Y. 2001-02 against addition of Rs.113.38 lacs by assessing officer has been decided in favour of the company,, however the department has gone to Tribunal for the same.

02. The Company has not provided for Gratuity and leave encashment to employees on accrual basis, which is not in conformity with AS-15 issued by ICAI. However, in the opinion of management the amount involved in negligible and has no impact on profit & loss account.

03. Earnings on foreign exchange – NIL.

04. Value of Import on C.I.F. Basis – NIL.

05. Value of foreign currency loan at year end Rs. NIL.

06. Figures of previous year have been regrouped, recasted and rearranged wherever necessary to make them comparable.

07. In the opinion of Board, the current assets, loans and advances are approximately of the value stated in the Balance sheet if realised in the ordinary course of business.

08. Stock has been valued, verified & Certified by the Management.

09. Amount is rounded up to nearest of rupees.

10. CONFIRMATION OF BALANCES The accounts of sundry debtors, creditors and other parties are as per books of the concern. These balances are subject to confirmation from respective parties.

For Socrus Bio Sciences Ltd.


Director

For Socrus Bio Sciences Ltd.





11. In cases where the vouchers and / or supporting are not available it has been accepted as per the information and explanations given to us by the management and as per the books of accounts maintained by the company that the expenses have been incurred wholly & exclusively for the purpose of business or for creation of the assets as the case may be.
12. Provision for taxation for the year under consideration has been made as per the provision of income tax Act, 1961.

13. **EARNING PER SHARE (EPS)** The earning per share computed as per the requirement under Accounting Standard 20 on earning per share issued by The Institute of Chartered Accountant of India, is as under:

Net profit/Loss after Tax as per P & L account	: Rs.-393622176
Weighted average No. of Equity Share outstanding	: 32002700
Basic and diluted earning per share	: Rs. 0

Due to loss of the Company, EPS will be NIL

14. **RELATED PARTY DISCLOSURE**

Related party disclosure as required by Accounting Standard 18 "Related Party Disclosure" are given below:-

1. Name of Related Party and its relationship

a) Associated Companies

- Socrus Pharmaceutical Ltd.
- Socrus Infotech Ltd.
- Charu Lifecare Private Ltd.
- Harsh Life care Private Ltd.
- Lush Pharma
- Amit Global Corporation

b) Key Management Personnel

- | | |
|------------------|----------|
| Rajiv Agnihotri | Director |
| Madhvi Agnihotri | Director |
| Premraj Alwa | Director |

Note: Related party relationship is identified by the Management and relied upon by the auditors.

2. Transaction carried out with related parties referred above in ordinary course of business.

Particulars	Key Management Personnel	Other
Remuneration	Nil (Nil)	Nil
Loans & Advances	Nil	Nil

For Socrus Bio Sciences Ltd.

Director

For Socrus Bio Sciences Ltd.

Director



15. DEFERRED TAX

In view of negative income and uncertainty of profit in future & uncertainty as to the utilization of deferred tax assets, even in part, in the foreseeable future, the deferred tax assets arising from unabsorbed depreciation and losses under tax laws have not been recognized.

16. SEGMENT REPORTING

1. Primary segment Information

(Rs . in lacs)

Business Segment	Pharma Division		Finance/Shares Division		Biotech Agro division		Other Income		Total	
	2011-12	2012-13	2011-12	2012-13	2011-2012	2012-2013	2011-2012	2012-2013	2011-2012	2012-2013
Segment Revenue External Sales	0	310.50	0	0	3016.00	1678.25	3.98	0	3019.98	1988.75
Segment Results PBIT	0	-350.27	-10	-110	651.52	-878.44	3.98	0	645.50	-1338.71
Less: other unallocable									0	-655.96
Profit before tax & EOI									645.50	-1994.67
Extra Ordinary item									0	-1941.55
Provision									0	0
-Current Tax									-133.37	0
-Deferred Tax/Liab									0	0
-FBT										
Profit(loss) after tax									512.13	-3936.22

In the management opinion it is not feasible to classify companies assets & liabilities among different segment.

2. Secondary Segment Information

The Company operates only in the Indian Market & agriculture products so there are no reportable geographical segments.

Goodwill has been fully written off during the year due to heavy losses ..

18. Balance Sheet Abstract & Companies general business profile as required by Part IV Schedule VI to the companies Act, 1956 is enclosed in ANNEXURE- ' B '

19 Additional information pursuant to the provisions of paragraphs 4,4b of Part II of schedule VI of the companies Act, 1956.

A. Auditors Remuneration	2012-13	2011-12
Audit Fees	Rs. 30000	20000
Tax Audit Fees	Rs. 10000	10000
Others	Rs. 5000	5500
Total	Rs. 45000	35500

For Socrus Bio Sciences Ltd.

Director



For Socrus Bio Sciences Ltd.

Director

Excludes service tax

B. Quantitative details are not made available to us.

As per our report of even date annexed

FOR & ON BEHALF OF BOARD

DIRECTOR

DIRECTOR

Place: Indore

Date: 05/09/2013


FOR: SHYAM NAGORI & CO.
CHARTERED ACCOUNTANTS

FRN-004573C


(SHYAM NAGORI)

PROPRIETOR

M.NO. 073609



For Socrus Bio Sciences Ltd.


Director

For Socrus Bio Sciences Ltd.


Director

